Dulaglutide Market Report 2024

The dulaglutide market size has grown strongly in recent years. It will grow from $3.87 billion in 2023 to $4.17 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth observed during the historical period can be linked to several factors, including the rising prevalence of type 2 diabetes, greater utilization rates, increased investments in research and development, a heightened focus on chronic diseases, and the expansion of personalized medicine.

The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The anticipated growth in the forecast period is expected to stem from several factors, such as an increase in clinical trials, rising obesity rates, an aging population, the expansion of telemedicine services, a rise in endocrinology clinics, and a growing adoption of electronic health records. Key trends during this period include advancements in technology, personalized medicine, telemedicine, digital health platforms, and mobile health applications.

The rising incidence of type 2 diabetes is projected to drive the expansion of the dulaglutide market in the future. Type 2 diabetes is a chronic condition characterized by insulin resistance or inadequate insulin production, leading to elevated blood glucose levels. This increase in type 2 diabetes is attributed to higher rates of obesity, unhealthy diets, and sedentary lifestyles. Dulaglutide aids in managing type 2 diabetes by enhancing insulin secretion and reducing glucagon levels in response to food intake, thereby lowering blood sugar levels. For example, as reported by the International Diabetes Federation in December 2021, diabetes affected 537 million adults aged 20 to 79 in 2021, with projections indicating an increase to 643 million by 2030 and 783 million by 2045. Consequently, the growing prevalence of type 2 diabetes is stimulating growth within the dulaglutide market.

Leading companies in the dulaglutide market are actively developing innovative products, including anti-diabetic drugs, to meet the rising demand for effective diabetes mellitus management. Anti-diabetic medications regulate blood sugar levels by enhancing insulin sensitivity, stimulating insulin production, or slowing glucose absorption from the digestive tract. For instance, in January 2024, Glenmark Pharmaceuticals Limited launched the first biosimilar of the anti-diabetic drug Liraglutide in India under the brand name Lirafit. This strategic move marks Glenmark's entry into the biosimilar market for anti-diabetic drugs, offering patients a more affordable treatment option while maintaining comparable efficacy and safety profiles to the original drug, meeting stringent regulatory standards.

In August 2023, Lupin Limited acquired two diabetic brands from Boehringer Ingelheim for €26 million ($28 million). This acquisition strengthens Lupin's position in the diabetes care market by expanding its product portfolio and market presence in diabetes management. Boehringer Ingelheim, a Germany-based company, is involved in the development and marketing of dulaglutide, a medication used to treat type 2 diabetes.

Major companies operating in the dulaglutide market are Merck And Co. Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Cipla Limited, Intas Pharmaceuticals Limited, Biocon Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Insulet Corporation, Nicholas Piramal India Limited, IPCA Laboratories Limited, Alembic Pharmaceuticals Limited, Ypsomed Holding AG, Wockhardt Limited, MannKind Corporation, Bioton S.A., Midas Pharma GmbH, Senova Technology Co. Ltd., Enomark.

North America was the largest region in the dulaglutide market in 2023. The regions covered in the dulaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dulaglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dulaglutide is a drug used to control blood sugar levels in people with type 2 diabetes. It belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which imitate the effects of the natural hormone GLP-1. Dulaglutide is given through a subcutaneous injection, usually once a week.

Dulaglutide is available primarily in syringe pens and multi-dose bottles. The syringe pen is a device for injecting medications such as dulaglutide. It integrates the medication and needle into a single, user-friendly instrument. This allows patients to adjust the dosage as needed, offering precision and convenience. The product is utilized in medical insurance, pharmaceuticals, and clinical research, and is available through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The dulaglutide market research report is one of a series of new reports that provides dulaglutide market statistics, including dulaglutide industry global market size, regional shares, competitors with a dulaglutide market share, detailed dulaglutide market segments, market trends, and opportunities, and any further data you may need to thrive in the dulaglutide industry. This dulaglutide research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dulaglutide market consists of sales of blood glucose monitors, needles, and injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.